SCHEMBL13199258

SCHEMBL13199258

Cc1cc(C(=O)NNC(=O)Cc2cccc(O)c2)ccc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
PLAU P00749 1/20 0.47
ELANE P08246 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
GAA P10253 2/20 0.47
HTT P42858 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
HSD17B1 P14061 2/20 0.45
HSD17B2 P37059 2/20 0.45
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.45
LMNA P02545 1/20 0.44
HSP90AA1 P07900 1/20 0.44
PDCD1 Q15116 1/20 0.44
CD274 Q9NZQ7 1/20 0.44
CYP3A4 P08684 1/20 0.44
ESRRG P62508 1/20 0.43
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2954979 0.85 ALDH1A1 (0.46) ALDH1A1PLAUELANESMN1; SMN2GAA
SCHEMBL13199160 0.85 TDP1 (0.55) ALDH1A1PLAUELANESMN1; SMN2GAA
SCHEMBL13199129 0.84 ALDH1A1 (0.57) ALDH1A1PLAUELANESMN1; SMN2HTT
SCHEMBL13199261 0.84 CA2 (0.50) ALDH1A1PLAUELANEHTTTDP1
SCHEMBL13199145 0.84 SMN1; SMN2 (0.62) ALDH1A1SMN1; SMN2GAAHTTTDP1
SCHEMBL13199260 0.84 ALDH1A1 (0.54) ALDH1A1PLAUELANESMN1; SMN2HTT
SCHEMBL13199110 0.83 KDM4E (0.55) ALDH1A1PLAUELANEHTTTDP1
SCHEMBL14098308 0.82 ALDH1A1 (0.43) ALDH1A1PLAUELANESMN1; SMN2HTT
SCHEMBL13199086 0.82 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2GAAHTTTDP1
SCHEMBL13199217 0.81 ALDH1A1 (0.53) ALDH1A1PLAUELANEGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 US disclosed
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 US disclosed
EP-1866280-B1 ACYL HYDRAZIDES AS KINASE INHIBITORS, IN PARTICULAR FOR SGK MERCK PATENT GMBH (DE) 2008-08-13 EP disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 US disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk SGK1, AGK, SGK2 ALDH1A1 1664/4885PLAU 2508/4885ELANE 3387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.